Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
Biologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
German Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).
Italian pharma company Recordati is putting €750m on the table to acquire UK-based specialty pharmaceutical company EUSA Pharma.
Sanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology.
US cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received €32m in funding by Enterprise Greece.
The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now!
Quell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.
Vaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m.